TerrAscend to Host Third Quarter 2025 Earnings Conference Call
TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that it will host a scheduled conference call to discuss the results for its third quarter ended September 30, 2025 on Thursday, November 6, 2025 at 5:00 p.m. Eastern Time. The Company will report its financial results for the third quarter 2025 the same day after market close.
| CONFERENCE CALL DETAILS | |
| Date: | Thursday, November 6, 2025 |
| Time: | 5:00 p.m. Eastern Time |
| Webcast: | https://app.webinar.net/6dvVkb2k4bz |
| Dial-in Number: | 1-888-510-2154 |
| Replay: | 1-289-819-1450 or 1-888-660-6345 Available until 12:00 midnight Eastern Time on Thursday, November 20, 2025 Replay Entry Code: 73897# |
About TerrAscend
TerrAscend is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including operations in Pennsylvania, New Jersey, Maryland, Ohio, and California through TerrAscend Growth Corp. and retail operations in Canada. TerrAscend operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including The Apothecarium, Cookies, Lemonnade, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com.
For more information regarding TerrAscend:
Ziad Ghanem
Chief Executive Officer
[email protected]
689-345-4114
[email protected]
Investor Relations Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
[email protected]
212-896-1254
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
- What Delta’s report tells investors in American and United
- Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share